(3.83.187.254)
Users online: 2499    [ij] [ij] [ij] 
Email id
 

Year : 2014, Volume : 1, Issue : 2
First page : ( 135) Last page : ( 138)
Print ISSN : 2322-0414. Online ISSN : 2322-0422. Published online : 2014  1.
Article DOI : 10.5958/2322-0422.2014.00529.3

Early Bone Marrow Response in Pediatric Acute Lymphoblstic Leukemia with Unfavourable and Favourable Presenting Features

Ghalaut Veena Singh1, Abrol Pankaj2, Sen Rajeev3, Manita4, Isha5,,*, Dahiya Kiran6, Ghalaut PS7, Singh Ragini8

1Senior Professor and Head, Department of Biochemistry, Pt. B.D.S. PGIMS, Rohtak, Haryana, India.

2Senior Professor, Department of Pediatrics, Pt. B.D.S. PGIMS, Rohtak, Haryana, India.

3Senior Professor and Head, Pt. B.D.S. PGIMS, Rohtak, Haryana, India.

4Resident, Department of Pathology, Pt. B.D.S. PGIMS, Rohtak, Haryana, India.

5Assistant Professor, Department of Biochemistry, Pt. B.D.S. PGIMS, Rohtak, Haryana, India.

6Associate Professor, Department of Biochemistry, Pt. B.D.S. PGIMS, Rohtak, Haryana, India.

7Senior Professor and Head, Department of Medicine, Pt. B.D.S. PGIMS, Rohtak, Haryana, India.

8Senior Resident, Department of Pathology, Pt. B.D.S. PGIMS, Rohtak, Haryana, India.

*Corresponding author email id: ishamalik111@gmail.com

Abstract

Acute lymphoblastic leukemia (ALL) is a neoplastic disease that results from multistep somatic mutations and remains the most common malignancy in children. This study was conducted on 30 pediatric patients diagnosed as ALL and early bone marrow response on day 7 and day 14 was correlated in patients with or without risk factors. The prognostic factors found to have significance were initial total leukocyte (TLC) count < 50000, immunophenotype and early clearance of peripheral blast cells at day 7 with P value of < 0.05. The three risk group patient for leukemic induction failure (LIF) can be considered as high TLC, T cell immunophenotype and patients with persistence of circulating blast cells at day 7.

Top

Keywords

Acute lymphoblastic leukemia, Bone marrow response, Blast cells, Immunophenotype, Remission .

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
518,999,201 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.